MicroRNAs and uses thereof
Described herein are polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
1. A nucleic acid selected from the group consisting of:
(a) the sequence of SEQ ID NO: 16563;
(b) a DNA encoding the sequence of (a), wherein the DNA is identical in length to (a);
(c) a sequence at least 90% identical to (a) or (b); and
(d) the complement of one of the nucleic acids of (a)-(c), wherein the complement is identical in length to the one of the nucleic acids of (a)-(c);
wherein the nucleic acid comprises a non-naturally occurring nucleotide.
2. A probe comprising a heterologous sequence, wherein the heterologous sequence consists a nucleic acid sequence selected from the group consisting of:
(a) the sequence of SEQ ID NO: 16563;
(b) a DNA encoding the sequence of (a), wherein the DNA is identical in length to (a);
(c) a sequence at least 90% identical to (a) or (b); and
(d) the complement of one of the nucleic acids of (a)-(c), wherein the complement is identical in length to the one of the nucleic acids of (a)-(c),
wherein the probe comprises at least one of a non-naturally occurring nucleotide and a label.
3. A vector comprising a heterologous sequence, wherein the heterologous sequence consists of a nucleic acid sequence selected from the group consisting of
(a) the sequence of SEQ ID NO: 16563;
(b) a DNA encoding the sequence of (a), wherein the DNA is identical in length to (a);
(c) a sequence at least 90% identical to (a) or (b); and
(d) the complement of one of the nucleic acids of (a)-(c), wherein the complement is identical in length to the one of the nucleic acids of (a)-(c).